INTELLIGENCE BRIEF
L’ORÉAL & KERING
L'Oréal's EUR 4 billion beauty deal is really a bet on longevity.
Luxury beauty · L'Oréal & Kering · April 2026 · One page summary of the full report
By Rafael Carlesso · Luxury Strategist · Milan, Italy
Bottom line
L'Oréal's EUR 4 billion purchase of Kering Beauté has been read as a routine deal in luxury beauty. It is two moves at once, and the larger one is not about beauty at all. The acquisition, which includes the niche house Creed and fifty year fragrance licences for Bottega Veneta, Balenciaga and Gucci from 2028, effectively closes the licensed designer beauty category to rivals at scale for the next half century. Alongside it sits a 50/50 joint venture aimed at the intersection of luxury, wellness and longevity, the most credible new structural growth category in the sector for the next decade, and at the closing on 31 March 2026 that venture was still, in operational terms, a press release. L'Oréal exits the structural winner. Kering exits financially repaired but offensively unproven. The real contest is no longer for beauty. It is for the wellness pivot, and it has barely begun.
The critical reading
The Creed line is the tell. Kering paid about EUR 3.5 billion for a single house, Creed, in June 2023, and presented it as the cornerstone of a new in house beauty division. Less than three years later it sold the entire division, Creed and the Bottega Veneta and Balenciaga build included, for EUR 4 billion. The press release calls this unlocking value and strengthening focus on the maisons. Both are true in the abstract and untrue at the level of the arithmetic: the whole expanded division fetched barely more than one brand had cost. The transaction crystallises value, it does not unlock it.
Strategic alliance is generous framing. The two companies describe the closing as a single alliance covering acquisition, licensing and joint venture. It is three different mechanisms with three different time horizons and three different risk profiles. The acquisition is a clean transfer of assets. The licence monetises L'Oréal's operational capability for fifty years. The joint venture is an option with no defined form. The venture is the thin element that lets the alliance language hold; remove it and the deal reads as acquisition plus licensing, which is mostly what it is.
The wellness venture is an option, not an asset. The longevity frontier is real, and the two parents are unusually well placed to build it together. But at the closing the joint venture had no chief executive, no first product, and no disclosed capital from either side. The asymmetry between them is structural: L'Oréal brings the longevity research and the operational engine, Kering brings brand reach inside houses that are themselves under repair, and a 50/50 split does not change who sets the pace. Without a defined first product, a neutral chief executive and a capital commitment by early 2027, the option decays into an alliance that lives in investor presentations and produces nothing.
Reading the numbers
The acquisition closed at EUR 4.0bn in cash on 31 March 2026. The Creed line tells the clearest story: Kering paid about EUR 3.5bn for that single house in June 2023 and sold the entire beauty division, Creed and the Bottega Veneta and Balenciaga build included, for EUR 4bn less than three years later. The two parents enter from opposite momentum. L'Oréal posted 2025 revenue of EUR 44.05bn and opened 2026 with first quarter sales of EUR 12.15bn, up 6.7 percent like for like, ahead of a beauty market that is itself growing. Kering posted 2025 revenue of EUR 14.7bn, down 13 percent as reported, with recurring operating margin falling from 14.5 percent to 11.1 percent and a net loss of EUR 29m on continuing operations. Gucci, which still accounts for close to 59 percent of group recurring operating profit, fell 22 percent as reported across the year and 14.3 percent in the first quarter of 2026, with its operating margin around 11 percent against a peak near 28 percent. The category backdrop stays favourable for the acquirer, with Givaudan reporting fine fragrance growth of 9.6 percent in the first quarter of 2026. The frontier the venture targets is large and compounding fast: the global wellness economy stood at about USD 6.8 trillion in 2024 and is projected to reach close to USD 9.8 trillion by 2029, a rate of around 7.6 percent a year that outpaces personal luxury goods over the same horizon.
This Brief gives you the read. The full report develops the analysis across creative leadership, channel and balance sheet, with the complete evidence base, the forward view and full sourcing. It is in Luxury Strategic Notes.